MARKET

ONCR

ONCR

Oncorus, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.190
+0.140
+4.59%
Closed 16:00 01/28 EST
OPEN
3.050
PREV CLOSE
3.050
HIGH
3.360
LOW
2.900
VOLUME
99.53K
TURNOVER
--
52 WEEK HIGH
26.77
52 WEEK LOW
2.900
MARKET CAP
82.33M
P/E (TTM)
-1.3731
1D
5D
1M
3M
1Y
5Y
PSTI, NES and VORB among mid-day movers
Gainers: Splash Beverage Group (NYSE:SBEV) +37%. Virgin Orbit Holdings (NASDAQ:VORB) +26%. TSR (NASDAQ:TSRI) +27%. Accolade (NASDAQ:ACCD) +26%. BARK (NYSE:BARK) +25%. Veru (NASDAQ:VERU) +22%. Nutriband (NASDAQ:NTRB) +22%. Nuverra Environmental Solutions (N...
Seekingalpha · 01/11 17:39
Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore ...
GlobeNewswire · 01/03 12:00
One Oncorus, Inc. (NASDAQ:ONCR) insider upped their stake in the previous year
Insiders were net buyers of Oncorus, Inc.'s ( NASDAQ:ONCR ) stock during the past year. That is, insiders bought more...
Simply Wall St. · 11/29/2021 11:13
Oncorus to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore ...
GlobeNewswire · 11/23/2021 12:00
Oncorus Files Prospectus Supplement Related To Sales Of Shares Having Offering Price Of Up To $50M
-Reuters
Reuters · 11/19/2021 21:45
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 11/18/2021 12:52
Oncorus Inc (ONCR) COO and Chief of Staff Stephen Harbin Bought $173,700 of Shares
GuruFocus News · 11/18/2021 10:15
70 Biggest Movers From Friday
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4 sales guidance above estimates.
Benzinga · 11/15/2021 09:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCR. Analyze the recent business situations of Oncorus, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ONCR stock price target is 31.00 with a high estimate of 45.00 and a low estimate of 19.00.
High45.00
Average31.00
Low19.00
Current 3.190
EPS
Actual
Estimate
-0.55-0.41-0.28-0.14
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 49
Institutional Holdings: 22.30M
% Owned: 86.39%
Shares Outstanding: 25.81M
TypeInstitutionsShares
Increased
16
316.70K
New
5
421.03K
Decreased
13
1.07M
Sold Out
7
229.66K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.75%
Pharmaceuticals & Medical Research
+1.94%
Key Executives
Chairman/Co-Founder/Executive Director
Mitchell Finer
President/Chief Executive Officer/Director
Theodore Ashburn
Chief Financial Officer/Treasurer/Secretary
John McCabe
Chief Operating Officer
Steve Harbin
Senior Vice President/Chief Scientific Officer
Christophe Queva
Senior Vice President
John Goldberg
Director
Barbara Yanni
Independent Director
Scott Canute
Independent Director
Luke Evnin
Independent Director
Mary Fenton
Independent Director
Spencer Nam
Independent Director
Eric Rubin
No Data
About ONCR
Oncorus, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing active viral immunotherapies to transform outcomes for cancer patients. Using its two distinct platforms, the Company is developing a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its lead product candidate, ONCR-177, is an intratumorally administered viral immunotherapy based on its oncolytic HSV-1 platform (oHSV Platform), which leverages the Herpes Simplex Virus type 1 (HSV-1). It is also developing a pipeline of product candidates based on its Synthetic Platform. This platform aims to enable repeat intravenous administration of viral immunotherapies in order to treat cancers that are less amenable to intratumoral injection due to safety and feasibility reasons, such as cancers of the lung.

Webull offers kinds of Oncorus Inc stock information, including NASDAQ:ONCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCR stock methods without spending real money on the virtual paper trading platform.